Poland’s Chief Pharmaceutical Inspector has halted the distribution of Lorazepam TZF nationwide, effective March 30, 2026, due to potential quality inconsistencies.
Lorazepam Distribution Suspended Nationwide
The Chief Pharmaceutical Inspector has suspended the distribution of Lorazepam TZF throughout Poland, with the decision taking effect immediately on March 30, 2026. The drug is used to treat anxiety and in emergency medicine.
The decision is preventative, stemming from research indicating a potential quality issue that could affect treatment efficacy, though the drug has not been permanently withdrawn.
Affected Products and Distribution Halt
The decision covers two injectable solution products. Distribution of these products is halted nationwide, preventing further market entry or dispensing.
Research Reveals Lower Dosage in Ampoules
Research conducted by the National Institute of Drugs revealed inconsistencies in a quality parameter. Specifically, some ampoules contained a lower volume of solution than specified, falling below the acceptable limit.
The manufacturer confirmed the irregularity in repeat testing. This could result in patients receiving a lower dose than intended, potentially reducing treatment effectiveness and raising safety concerns.
Systemic Suspension Despite Limited Batch Findings
While the research focused on a specific batch, the suspension applies to the entire product. This is due to pharmaceutical law, which holds the manufacturer responsible for risks associated with the drug’s market presence, resulting in a systemic rather than isolated suspension.
Impact on Patients and Hospitals
Lorazepam in injectable form is primarily used in emergency situations and for acute anxiety. The distribution halt requires medical facilities to immediately cease use and find alternative medications, potentially causing short-term local shortages.
However, alternative benzodiazepines are available, ensuring patients can still receive treatment.
Manufacturer’s Explanation Rejected by GIF
The manufacturer suggested potential errors in specification limits, differing interpretations of results (including rounding), and no issues with the production process, assessing the risk to patients as “low to moderate.”
The GIF rejected these explanations, emphasizing that the existing specification is binding and any deviations require formal approval from the registration authority. The decision remains in place to protect public health.
Decision is Immediately Enforceable, Appeals Possible
The decision is immediately enforceable, but the manufacturer can still pursue legal avenues. However, even filing an appeal does not suspend the decision’s execution.
Preventative Measure, Not Immediate Danger
The suspension is a preventative measure, not an indication that the drug is dangerous. The primary concern is the risk of administering too low a dose, uncertainty regarding long-term quality stability, and protecting patients from potentially inadequate therapy.
Even minor deviations are significant, particularly for medications used in emergency situations.
Key Questions and Answers for Patients
Is Lorazepam permanently withdrawn? No, the distribution is temporarily suspended pending investigation.
Should patients be concerned? The decision is preventative, focusing on dosage efficacy rather than immediate life threats.
Are there alternatives? Yes, other benzodiazepines are available for similar indications.
Can I continue using Lorazepam at home? Consult with a doctor regarding continued use.